Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01797471 · ClinicalTrials.gov registry record · NA
Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer
A NA study, sponsored by University of Miami.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01797471 is a NA study that was terminated before completion, run by University of Miami. The registered enrollment target is 1 participants.
The verdict
NCT01797471, a NA study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The investigators aim to evaluate the safety of delivering a one-time single fraction of Lattice Extreme Ablative Dose (LEAD) radiotherapy followed one day later by standard-dose, conventionally fractionated concurrent chemotherapy and radiation delivered over 6 weeks in patients with bulky stage III non-small cell lung cancer in the setting of a single-arm phase I clinical trial. The investigators hypothesize that the addition of a one-time single fraction of LEAD radiation is safe and feasible, and will not result in additional toxicity above that expected with standard-dose concurrent chemotherapy and radiation alone.
Interventions
- RADIATION Lattice Extreme Ablative Dose (LEAD) Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-11-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01797471
The ClinicalTrials.gov registry entry for NCT01797471 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lattice Extreme Ablative Dose (LEAD) Radiation Therapy is the first listed.
NCT01797471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01797471 about?
NCT01797471 is a clinical study titled "Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer". The investigators aim to evaluate the safety of delivering a one-time single fraction of Lattice Extreme Ablative Dose (LEAD) radiotherapy followed one day later by standard-dose, conventionally fractionated concurrent chemotherapy and radiation delivered over 6 weeks in patients with bulky stage II...
What is the current status of trial NCT01797471?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2013-03. Estimated completion is 2013-11-06.
What interventions are being tested in trial NCT01797471?
The interventions under investigation include: Lattice Extreme Ablative Dose (LEAD) Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01797471?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.